Results 41 to 50 of about 5,935 (185)

Establishment of Haemonetics TEG 6s Reference Interval in Healthy Dogs

Veterinary Clinical Pathology, EarlyView.
ABSTRACT Background A thromboelastogram viscoelastic monitor (the TEG 6s) has recently become available for use in veterinary patients. It is therefore necessary to establish reference intervals for the new device in each species where it is employed.
Kaylan Whetstone, Justin Heinz, Lonnie E. Grantham II, Michaela Stavropoulos, Chelsie Hall, Floris C. Dröes, Thomas H. Edwards   +6 more
wiley   +1 more source

Estudo experimental do uso de um antagonista do receptor da glicoproteína IIb/IIIa das placentas na prevenção de tromboses em microanastomoses vasculares An experimental study on the use of an antagonist of the platelet glycoprotein IIb/IIIa receptor in the prevention of thrombosis in vascular microanastomoses

Acta Ortopédica Brasileira, 2000
O autor comparou, experimentalmente, a eficácia da droga abciximab, um antagonista do receptor da glicoproteína IIb/IIIa das plaquetas, na prevenção da trombose nas microanastomoses arteriais em ratos Wistar.
Márcio Issamu Oide
doaj   +1 more source

Abciximab [PDF]

Reactions Weekly, 2021
openaire   +3 more sources

Lack of Differences in the Pharmacokinetics of Therapeutic Monoclonal Antibodies Between Japanese and Non‐Japanese Individuals

The Journal of Clinical Pharmacology, Volume 66, Issue 8, August 2026.
Abstract Evaluation of the pharmacokinetics (PK) of new drugs in Japanese individuals is regularly requested by the Japanese regulatory agency prior to participation in global clinical trials or for bridging approaches for regulatory approval. However, the need for PK assessments in the Japanese population may be less compelling for monoclonal ...
Paridhi Gupta, Ashish Sharma, Bernd Meibohm   +2 more
wiley   +1 more source

Antibody–Drug Conjugates and Peptide–Drug Conjugates: Current Understandings and Future Perspectives

MedComm, Volume 7, Issue 8, August 2026.
The graphic summarizes the design principles, intracellular trafficking, clinical progress, challenges, and future directions of antibody–drug conjugates (ADCs) and peptide–drug conjugates (PDCs). ADCs consist of a tumor‐targeting antibody, a chemical linker, and a potent payload, whereas PDCs use peptide ligands to deliver cytotoxic, radionuclide, or ...
Ruxi Zheng, Shuiquan Li, Zhigang Zhang, Mengke Niu, Jing Fei, Jiaojiao Zhang, Jianwei Zhou, Kongming Wu, Ming Yi, Tianye Li   +9 more
wiley   +1 more source

Rationale for intracoronary administration of abciximab

, 2007
The present review aims to describe the pharmacological aspects as well as the available clinical data supporting the choice of intracoronary route of administration for abciximab, an antiplatelet drug used in patients with acute coronary syndromes ...
Trani C., Romagnoli E., Crea F., Burzotta F.   +3 more
core   +2 more sources

Comparison of angioplasty with infusion of tirofiban or abciximab and with implantation of sirolimus-eluting or uncoated stents for acute myocardial infarction: the MULTISTRATEGY randomized trial.

, 2008
Abciximab infusion and uncoated-stent implantation is a complementary treatment strategy to reduce major adverse cardiac events in patients undergoing angioplasty for ST-segment elevation myocardial infarction (STEMI).
N. d. Cesare, R. Moreno, S. Colangelo, M. Valgimigli, G. Parrinello, A. E. Rodriguez, M. E. of Single High Dose Bolus Tirofiban vs Abciximab With Sirolimus Eluting Stent or Bare Metal Stent in Acute Myocardial Infarction Study Investigators, G. Percoco, M. S. Nazzaro, VASSANELLI, Corrado, F. Prati, R. Ferrari, L. Bolognese, G. Pasquetto, T. Piva, M. Ferrario, I. Sheiban, G. Campo   +17 more
core   +1 more source

TEG®6s system measures the contributions of both platelet count and platelet function to clot formation at the site-of-care

Platelets, 2020
Knowledge of platelet count and function is key to ensuring appropriate hemostatic management. We hypothesized that the novel, portable TEG®6s coagulation assessment system could evaluate the contribution of both platelet count and function to clot ...
Joao D. Dias, Carlos G Lopez-Espina, Kevin Bliden, Paul Gurbel, Jan Hartmann, Hardean E Achneck   +5 more
doaj   +1 more source

Efficacy and Safety of Tirofiban for the Management of Acute Ischemic Stroke: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials (RCTs)

Brain and Behavior, Volume 16, Issue 6, June 2026.
Graphical representation of the comparative efficacy and safety of intravenous tirofiban for acute ischemic stroke in randomized controlled trials. ABSTRACT Background: Tirofiban is a GP IIb/IIIa inhibitor, an anti‐platelet drug that is used in ischemic stroke or acute coronary syndromes.
Dorothy Lim Bullecer, Cara Mohammed, Julie Anne De Lima Loiola, Mary Gabrielle Te Chy, Samratul Fuadah Ramli, Abimbola Sodiq Hussein, Wasid Bin Showkat, Thahsin Taikadan, Sarika Mutyala, Muhammad Ayyan, Muhammad Aemaz Ur Rehman, Adeel Ahmad, Asma'a Munasar Ali Alsubari   +12 more
wiley   +1 more source

Stent Thrombosis: A Narrative Review From Pathophysiology to Therapy

Clinical Cardiology, Volume 49, Issue 4, April 2026.
Stent thrombosis remains a life‐threatening complication of PCI driven by complex interactions between stent design, procedural factors, thrombogenic milieu, and inflammation. This review integrates pathophysiological mechanisms with contemporary and emerging therapeutic strategies, highlighting optimized PCI, tailored antithrombotic therapy, and novel
Emanuele Cecchi, Andrea Grasso Granchietti, Ruggero Mazzotta, Manuel Garofalo, Giorgia Panichella, Giuseppe Iula, Francesca Maria Di Muro, Silvia Menale, Rossella Marcucci   +8 more
wiley   +1 more source